Lifecore Biomedical, Inc. announced in connection with the issuance of the Series A convertible preferred stock, Nathaniel Calloway, PhD and Christopher Kiper were appointed to the company's Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | -2.18% | -2.67% | -5.82% |
Apr. 19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.82% | 178M | |
+37.74% | 723B | |
+34.64% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.89% | 244B | |
+10.02% | 208B | |
-4.42% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Lifecore Biomedical, Inc. Announces Board Appointments